Homburger advised OC Oerlikon on the completion of the divestment of its Barmag textile machinery business for manmade fibers to Rieter
On February 2, 2026, OC Oerlikon announced that it has completed the divestment of its Barmag textile machinery business for manmade fibers to Rieter at an enterprise value of CHF 850 m with an earn-out of up to CHF 100 m. With the closing of this transaction, Oerlikon becomes a pure-play surface technology company, serving …
Homburger secures revision of CAS award for U.S. Olympic gymnast Jordan Chiles before the Swiss Federal Supreme Court
Homburger successfully represented U.S. artistic gymnast Jordan Chiles in proceedings before the Swiss Federal Supreme Court in connection with the 2024 Olympic Games. On January 23, 2026, the Swiss Federal Supreme Court upheld a request for revision filed on behalf of Ms. Chiles and set aside a Court of Arbitration for Sport (CAS) award that …
Homburger advised the shareholders of Clariness AG on the sale of 100% of their shares to SubjectWell, Inc.
On January 27, 2026, SubjectWell, Inc. announced the acquisition of Swiss-based Clariness AG and the merger of Clariness and SubjectWell to form one of the largest global, full-service patient recruitment platforms, combining global scale, scientific rigor, and patient-first design to transform clinical trial access and execution worldwide.
Homburger advised UBS Switzerland AG on the issuance of CHF 685 m aggregate amount Fixed Rate Covered Bonds
On January 15, 2026, UBS Switzerland AG successfully completed its issuance of CHF 150 m 0.435 per cent. Fixed Rate Covered Bonds due January 15, 2029, CHF 190 m 0.745 per cent. Fixed Rate Covered Bonds due January 15, 2032, and CHF 345 m 1.0225 per cent. Fixed Rate Covered Bonds due January 15, 2036, …
Homburger advised Zürcher Kantonalbank on the issuance of EUR 500 m 2.950 per cent. Fixed Rate Bonds
On January 26, 2026, Zürcher Kantonalbank successfully completed its issuance of EUR 500 m 2.950 per cent. Fixed Rate Bonds due January 26, 2031 (the Bonds). The senior unsecured Bonds have been issued under Zürcher Kantonalbank’s Swiss base prospectus consisting of the applicable summary and securities note for the issue of bonds and short term …
Homburger advised Fastned B.V. on a green loan credit facility of initial EUR 100 m in committed capital with an additional EUR 100 m option
January 23, 2026 Homburger acted as Swiss counsel to Fastned Tico Holding I B.V., a direct subsidiary of Fastned B.V., in its capacity as borrower in connection with a Dutch law-governed EUR 100 m committed senior multicurrency term facility agreement with an additional EUR 100 m option with a European lending syndicate consisting of ABN …
Homburger advised Raiffeisen on the issuance of CHF 100 m Green Bonds by HIAG
On January 15, 2026, HIAG Immobilien Holding AG, a leading player in the real estate industry in Switzerland that covers the entire property value chain of portfolio/asset management, site development and transaction management,
Homburger advised UBS Group AG on its issuance of EUR 3 bn Fixed Rate/Fixed Rate Callable Senior Notes under its Senior Debt Programme
On January 13, 2026, UBS Group AG successfully completed its issuance of EUR 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due February 2031 and EUR 1.5 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due January 2037 under its Senior Debt Programme.
Homburger advised Baseline Wealth Management and its founder on its sale to Creative Planning
On January 13, 2026, Baseline Wealth Management, an established FINMA-registered portfolio manager and SEC-registered investment advisor (RIA) with offices in Geneva and Zurich, announced it has joined Creative Planning, one of the largest RIAs in the United States.
Homburger advises Santhera on its licensing of AGAMREE® to Nxera Pharma in APAC countries
On January 8, 2026, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had signed an exclusive licensing agreement with Nxera Pharma, a biopharmaceutical company listed on the Tokyo Stock Exchange, for the development, manufacturing and commercialization of AGAMREE® for the treatment of Duchenne muscular dystrophy in Japan, South Korea, Australia and New Zealand. Santhera …